Suzhou Stanway Biotechnology

Suzhou Stanway Biotechnology is a clinical-stage biotechnology company specializing in the development of mRNA-based vaccines and therapeutics. Headquartered in Suzhou Biobay, China, the company leverages its proprietary mRNA synthesis and lipid nanoparticle (LNP) delivery platforms to address critical needs in infectious diseases and oncology. Its lead candidate, SW-0123, is an mRNA vaccine for COVID-19 that has entered clinical trials. Stanway Bio is focused on building a robust pipeline that includes vaccines for rabies and various cancer indications, supported by a team with extensive experience in nucleic acid drug development.